Phase 4 N=41 Treatment

Iloperidone in Mixed States of Bipolar Disorder

Bipolar Disorder

Bottom Line

View on ClinicalTrials.gov: NCT02413918 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2017

Primary outcome: Primary: Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores — 35.7; 61.8; 25; 48 percentage change in score on BISS scale — p=<0.0094

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: iloperidone (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: The University of Texas Health Science Center at San Antonio
Primary completion: Apr 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores	35.7; 61.8; 25; 48	<0.0094 sig

Summary

1. To assess the acute and long-term bimodal efficacy of iloperidone (IL), as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD. 2. To assess background, baseline features, and behavioral components which characterize treatment response/non-response in the acute and long term management of MS

Eligibility Criteria

Inclusion Criteria

Male or female;
Age 18 years and older
Patients on:
Li at a stable dose for 2 weeks or longer, and a serum level at screening of greater than or equal to 0.5 mEq/l OR
DIV dose for 2 weeks or longer, and a serum level at screening of greater than or equal to 45 ug/ml OR
LAM (dosage/day ≥100mg) at a stable dose for 2 weeks or longer OR
Any combination 3a, 3b, or 3c
Patients meeting DSM-IV TR diagnosis of bipolar disorder, I or II, as assessed using the MINI, (Sheehan et al., 1998) PLUS any ONE of criteria 5 or 6 or 7
Patients meeting DSM-IV TR diagnostic criteria for a mixed manic episode with Young Mania Rating Scale (YMRS) score>/=14 and Montgomery Asberg Depression Rating Scale (MADRS) score>/=14
Patients meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score>/=14 PLUS Montgomery Asberg Depression Rating Scale (MADRS) score>/=14 ;
Patients meeting DSM-IV TR diagnostic criteria for a major depressive episode with the simultaneous presence of MADRS score>/=14 PLUS meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score>/=14

Exclusion Criteria

Patients with a current Axis I diagnosis of schizophrenia, schizophreniform disorder, schizotypal disorder, bipolar disorder with psychotic sub-type that requires hospitalization, drug induced mania or AIDS induced mania
Women with a positive pregnancy test or who are lactating
Women of child-bearing potential who are not practicing a clinically accepted method of contraception
Patients with general medical conditions that contraindicate psychoactive medications or uncontrolled medical disorder or central nervous system diseases.
Patients whose clinical status requires inpatient or day hospital treatment
History of severe side effects associated with therapeutic doses of Li, DIV, LAM
Alcohol or drug dependent at time of enrollment
Suicidal at time of enrollment.
Current or previous exposure to iloperidone
Patients taking medication that cause QTC prolongation
Patients with serious cardiac disease

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02413918). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.